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Abstract: The pathogenesis of atherosclerosis includes the assignment of a critical role to cells of the mono-
cyte/macrophage lineage and to pro-inflammatory cytokines. Niacin is known to improve lipid metabolism and to produce 
beneficial modification of cardiovascular risk factors. The aim of this work was to investigate if Niacin is able to modu-
late pro-inflammatory cytokine production in macrophages in a murine model of atherosclerosis. For this purpose 
C57Bl/6J mice fed with atherogenic diet (AGD) or with conventional chow diet were used. The AGD group showed an 
increase in body weight and in total plasma cholesterol, with no differences in triglyceride or HDL levels. Lesions in arte-
rial walls were observed. The characterization of Niacin receptor showed an increase in the receptor number of macro-
phages from the AGD group. Macrophages from control and AGD animals treated in vitro with an inflammatory stimulus 
showed elevated levels of IL-6, IL-1 and TNF-α, that were even higher in macrophages from AGD mice. Niacin was able 
to decrease the production of pro-inflammatory cytokines in stimulated macrophages. Similar effect of Niacin was ob-
served in an in vivo model of inflammation. These results show an attenuating inflammatory mechanism for this therapeu-
tic agent and would point out its potential action in plaque stabilization and in the prevention of atherosclerosis progres-
sion. Furthermore, the present results provide the basis for future studies on the potential contribution of Niacin to anti-
inflammatory therapies. 
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INTRODUCTION 
 Atherosclerosis is a complex vascular disease that usually 
begins in the first decade of life and is now recognized as an 
inflammatory illness [1]. It is a process characterized by the 
accumulation of lipids, mononuclear cells, fibrous compo-
nents, and calcium in the arteries [2]. It begins in early life 
and progresses through adulthood, exacerbated by hyperten-
sion, diabetes, hyperlipidemia, smoking, and obesity [2-4]. 
Vascular injury, recruitment of monocyte cells and infiltra-
tion of foam cells (lipid-laden macrophages) in combination 
with T lymphocytes, promotes the lesion formation [2,4]. 
The deposition of lipids is accompanied by migration and 
proliferation of smooth muscle cells.  
 Nicotinic acid, also known as Niacin, is well established 
for the treatment of dyslipidemia, as it has a potent effect in 
lowering plasma LDL-cholesterol and raising HDL-choles-
terol. Numerous clinical studies have demonstrated a signifi-
cant reduction in cardiac events and in cardiovascular  
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disease-related mortality with Niacin treatment [5, 6]. How-
ever, the exact mechanism of action of this drug is still not 
fully understood. The orphan receptor GPR109A, a G-
protein-coupled receptor (GPCR) was recently demonstrated 
to bind and to be activated by Niacin [7, 8]. This receptor has 
recently been given the HGNC approved gene symbol, 
NIACR1, but it is also termed HM74a in humans and 
PUMA-G (for protein up-regulated in macrophages by inter-
feron-gamma) in mice [7, 8]. The discovery of a very highly 
expressed GPR109A that binds Niacin with high affinity in 
adipocytes has conducted the research of the antilipolytic 
effects of Niacin in adipose tissue [7, 8]. Acting through the 
GPR109A it was shown that Niacin suppresses the release of 
free fatty acids (FFA) from adipose tissue, and it is believed 
that the consequent reduction in free fatty acid flux to the 
liver leads to the decreased synthesis of triglyceride and of 
VLDL production by substrate depletion. In patients nico-
tinic acid reduces LDL-cholesterol and increases HDL cho-
lesterol [9]. The observed reduction in the progression of 
atherosclerosis and in cardiovascular morbidity with Niacin 
would be solely due to its lipid modifying effects [5].  
 However, inflammation is a key component of athero-
sclerosis and genes coding for inflammatory or anti-
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inflammatory molecules are, therefore, good candidates for 
estimating the risk of developing atherosclerosis [10-12]. 
Accordingly, the production of high inflammatory molecules 
has been associated to atherosclerosis [13-15]. It is possible 
to postulate that drugs with a positive control of inflamma-
tion might play a protective role against atherosclerosis and 
would be potential therapeutic candidates to prevent 
atheroma formation.  
 A key question is whether the activity of nicotinic acid 
via GPR109A expressed on the surface of the adipocyte is 
sufficient to account for the overall clinical efficacy ob-
served. In addition to its expression on adipocytes, 
GPR109A is known to be highly expressed also in spleen, 
lung, and lymphoid cells [8]. To date, there are studies sug-
gesting GPR109A-mediated effects outside the adipose tis-
sue. Experimental findings indicating high expression of 
GPR109A in lymphoid cells together with the observation of 
its up-regulation in murine macrophages by cytokines like 
IFN-γ [16], would suggest a role for GPR109A in immunity 
and inflammation. In recent years, the anti-inflammatory 
effects of Niacin have attracted attention, but the exact 
knowledge on the mechanisms involved in these actions is 
still missing. Additionally, some previous studies in vitro 
and in vivo have revealed that Niacin has anti-inflammatory 
properties that are independent of its effects on lipid regula-
tion [17-21]. 
 In this scenario, the aim of the present work was to inves-
tigate if Niacin actions involved the modulation of pro-
inflammatory cytokine production in macrophages from 
mice submitted to an atherogenic diet, analyzing the in-
volvement of macrophage Niacin receptor in these effects. 
To study experimental atherosclerosis we use C57BL/6J 
mice strain as it was demonstrated to be the most atheroscle-
rosis sensitive strain [22]. 
MATERIALS AND METHODS 
Mice  
 Inbred female C57Bl/6J mice, 4 weeks old, were ob-
tained from the Facultad de Veterinaria, Universidad de 
Buenos Aires (UBA), Argentina and were housed in the 
animals facility of the Centro de Estudios Farmacológicos y 
Botánicos (CEFYBO)- Consejo Nacional de Investigaciones 
Científicas y Técnicas (CONICET)- UBA. Animals were 
maintained on a 8:00 am to 8:00 pm light/dark cycle under 
controlled temperature (18-22ºC). All animal experiments 
and care were in accordance with the principles and guide-
lines of the Guide for the Care and Use of Laboratory Ani-
mals, US National Research (NIH) accredited by the Institu-
tional Committee for use and care of Laboratory Animal 
(CICUAL, Facultad de Medicina, Universidad de Buenos 
Aires, Argentina). It is worth to note that this murine strain 
was previously shown to develop diet-induced fatty streak 
lesions [23]. 
Animal model of atherosclerosis 
 A total of 125 female mice were used for atherogenic diet 
and other 125 animals were assigned for the chow diet 
group. Animals were randomly assigned to two groups: one 
that was fed with conventional chow diet (Control mice) and 
the other with the atherogenic diet (AGD mice). This diet 
was a pellet obtained by mixing an special argentine com-
mercially breeding chow containing 10% fat, 26 % proteins, 
34 % carbohydrate, with the addition of 15% dairy butter. As 
previously described this type of diet exerts the largest 
atherogenic action [23,24]. The standard diet contains 26% 
proteins, 45 % carbohydrate and 5% fat. The two diets con-
tain AIN-93 mineral and vitamin mix. 
Histological Studies 
 Mice were anesthetized with 28 % (w/v) chloral hydrate, 
0, 1 ml/ 100g of body, and perfused with 4% paraformalde-
hyde in phosphate buffer 0, 1 M, pH 7.4 through the ab-
dominal aorta. Later this artery was dissected and the tho-
racic and abdominal segment selected and post fixed in the 
same solution during 2 hours, immersed overnight in phos-
phate buffer 0, 1 M, pH 7.4 and them embedded in paraffin 
for optical microscope evaluation. Sections of 4 µm were cut 
and mounted in silanized slices.  
 For immunohistochemical studies, artery sections (4 µm) 
were incubated overnight with the primary antibody (α- 
Actin, 1:100, monoclonal mouse antibody, 1A4, DAKO). 
Following several wash steps with PBS, artery sections were 
incubated with the proper secondary antibody (Vector Labo-
ratories Inc., Burlingame, CA, USA) and followed by incu-
bation with a biotin streptavidin complex (HRP Histo Mark, 
Caramillo, CA, USA). After washing in PBS, sections were 
developed and AEC substrate kit (Invitrogen Gaithersburg, 
MD, USA) until staining was optimal as examined by light 
microscopy using Leica Microscopes. Images were collected 
using a CCD video camera CU-M50 (Sony Inc.). Pictures 
were analyzed and compiled using Adobe Photoshop 8.0 
CS3. 
Purification of Murine Macrophages 
 Macrophages were purified from peritoneal exudates as 
previously described [25]. Briefly, after sacrifice, mice were 
injected intraperitoneally with 10 ml of sterile PBS and after 
10 min the ascitic fluid was removed. This fluid was centri-
fuged 10 min at 200g and the cell pellet was washed twice 
with PBS. Cells were seeded at a concentration of 
1x106cel/cm2 in culture medium (RPMI 1640, supplemented 
with 10% FCS and antibiotics) in 60x15mm Petri Dish with 
Cover (Corning®) to purify adherent cells. After 2 h non-
adherent cells were discarded and macrophages were re-
moved by trypsin treatment. This procedure renders ap-
proximately 2-4 x 106 macrophages per mouse. 
Expression of GPR109A in Macrophages by [3H]-
Nicotinic Acid Binding 
 Saturation binding assays were carried out on purified 
macrophages according to Lorenzen et al., 2001 [26] and 
Wise et al., 2003 [8]. Briefly, 6 x 106 cells per binding point 
in a total volume of 250 μl were incubated with increasing 
concentrations of [5,6-3H] nicotinic acid (American Radio-
labeled Chemicals Inc, 50 Ci/mmol) ranging from 10 to 200 
nmol/L for 3 h at room temperature with agitation. Nonspe-
cific binding was assessed in the presence of 1 mM nicotinic 
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acid. The bound ligand was recovered onto presoaked GF/B 
filters, washed four times with 1 ml of ice-cold binding 
buffer, and measured by liquid scintillation counting. 
Cytokine Production 
 1 x 106 cells were incubated in 1 ml of supplemented 
medium (RPMI-1640 with 10% fetal calf serum and antibiot-
ics) on 24 well-plates. These cells were incubated alone or 
with increasing concentrations of Niacin, ranging from 50 to 
1000 M and stimulated with lipopolysaccharide (LPS) and 
interferon- (IFN-) (Sigma Aldrich Co.) for 24 hours as 
previously described [27]. After incubation cell-free super-
natants were obtained and the cytokine levels indicated in the 
Result section were measured by enzyme-linked immu-
nosorbent assays (ELISA) using commercially available kits, 
following the manufacturer instructions. To further charac-
terize the role of the GPR109A receptor, that is coupled to G 
protein, studies were also performed on macrophages pre-
treated with an inhibitor of G protein coupling, namely per-
tussis toxin (PTX), for 18 h. 
Inflammation Mice Model 
 An additional group of mice (n=12) was used to study the 
effect of Niacin on in vivo cytokine production. For this 
purpose animals were divided in four experimental groups: 
injected intraperitoneally with PBS or 500 g (20 mg/kg) of 
LPS (Escherichia coli 026:B6) and simultaneously oral 
treated or non-treated with Niacin (250 mg/Kg)). Twelve 
hour after the injection, intraperitoneal macrophages were 
obtained and incubated in supplemented medium for addi-
tional twelve hours to collect supernatants for cytokine 
analysis [28]  
Statistical Analysis 
 Group differences were tested by one-way analysis of 
variance (ANOVA). When multiple comparisons were nec-
essary after ANOVA, the Student-Newman-Keuls test was 
applied. Weight analysis was done with repeated measures 
ANOVA. When results showed not normally distribution the 
non-parametric Mann-Whitney test was performed. Differ-
ences between means were considered significant when p< 
0.05. 
RESULTS 
Differences in Lipid Profile and Arterial Lesions between 
Control and AGD Mice 
 To validate the atherogenic response in AGD mice, se-
rum lipid levels were measured in peripheral blood samples 
and tissue lesions were evaluated in aortic sections by im-
munohistochemistry. As shown in Fig (1), AGD, but not 
 
Fig. (1). Characteristics of mice submitted to the atherogenic diet. The mean weights of n=30 control (circles) or 30 atherogenic diet-fed 
(AGD mice, squares) mice recorded at different weeks are depicted (panel A). Plasma levels of glycemia (panel B) and lipid profile: triglyc-
erides (panel C) cholesterol (panel D), HDL (panel E), LDL (panel F) and VLDL (panel G) were determined for control and AGD mice. 
Results shown are the mean ± SEM of n = 30 mice from each group. Differs significantly from control animals, * p<0.05, ** p<0.01. 
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control mice, displayed an increase in body weight and in 
cholesterol levels. No changes in triglycerides, glucose, 
HDL, LDL or VLDL were observed in both groups. More-
over these animals had important aortic lesions that were not 
present in control mice. As can be seen in Fig. (2), control 
animals showed aortic arteries sections without morphologi-
cal changes. All layers were preserved and no evidence of 
cell migration or endothelial activation was observed (panel 
A). In AGD mice the arteries wall sections showed signifi-
cant alterations such as inner elastic layer disruption, disor-
ganization of smooth muscle cells (SMC) from middle layer, 
vacuolization and ulterior migration of smooth muscle cells 
to the neointimal layer and an aortic wall intimal thickening 
(panel B and E). Also, in control animal’s contractile cells 
(differenciated) predominate over the other group; opposite 
what was found in AGD animals (panel F). It is worth noting 
that myoepithelial cells were finally confirmed by their 
strong positive immunohistochemical staining with anti--
actin antibody (Panel C). Moreover, the presence of CD68+ 
cells (macrophages) was observed (Panel D). 
Up-regulation of Nicotinic Acid Receptors in Macro-
phages from AGD Mice 
 To evaluate if the changes compatible with atherosclero-
sis induction in AGD mice were accompanied by modifica-
tions in macrophages, Niacin receptor expression was stud-
 
Fig. (2). Aortic lesions in AGD mice. Histological sections of aortic arteries, representative of n=10 sections from different animals of each 
group, are shown. Panel A: Control aortic wall stained with Hematoxylin-eosin (HE) shows that all layers are conserved. Panel B: HE stain-
ing of aortic wall from AGD mice: 1. rupture of the internal elastic layer; 2. migration of smooth muscle cells into the neo-intima; 3. vacuoli-
zation of sub-intimal smooth muscle cells; 4. disruption of smooth muscle. Panel C: immunohistochemical staining with anti--actin anti-
body: 1-myoepithelial cells; 2-endothelial cells. Pannel D: immunohistochemical staining anti-CD68 (macrophages). 1- myoepitelial cells, 2-
macrophage. Panel E: size of the intimal aortic wall. Panel F average number of medial smooth muscle cells (SMCs). This value of intimal 
cells was determined by counting nuclear profiles of two types of intimal cells: “synthetic”, undifferentiated cells (gray), and “contractile”, 
differenciated cells: (white). Results are expressed as cells per unit area of intima (i.e., cells per square millimeter) in control and treated 
(AGD) animals. Data represent mean ± SEM; n=3 in each group (Panel E and F), ** p< 0.01 and *** p<0.001 
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ied on purified macrophages from control and AGD mice by 
[3H] Nicotinic acid binding. As can be seen in Fig. (3), a 
saturable and specific (more than 80%) binding of radio-
labelled Niacin was obtained in these cells. Scatchard analy-
sis of saturation curves showed that macrophages from AGD 
mice have twice binding sites than control mice. No differ-
ences were found in the nicotinic acid receptor affinity, as 
similar Kd were observed. 
Niacin-mediated Modulation of Pro-inflammatory Cyto-
kines 
 As basal macrophage cytokines levels in both control and 
AGD mice are too low, we used two experimental ap-
proaches to evaluate the effect of Niacin on cytokine produc-
tion: i. by assaying in vitro cytokine secretion from macro-
phages after a pro-inflammatory stimulus and ii. by evaluat-
ing the production of cytokines in macrophages from mice 
injected with an inflammatory dose of LPS. To induce the 
production of pro-inflammatory cytokines, in vitro macro-
phages were stimulated with LPS and IFN- as described 
[27]. To study the action of Niacin on pro- inflammatory 
cytokine production, cells were stimulated in the absence or 
presence of increasing concentrations of Niacin (ranging 
from 50 M to 1000 M) and Tumor Necrosis Factor- 
(TNF, Interleukin-1 (IL-1) and Interleukin-6 (IL-6) levels 
were measured in cell free supernatants of these cultures. As 
shown in Fig. (4) basal cytokine production is higher in 
macrophages from AGD than those from control mice. Pro-
inflammatory cytokine production was reduced in the pres-
ence of 500 to 1000 M Niacin both in control and AGD 
mice, being the effect more evident in AGD than in control 
animals. To further characterize the role of the GPR109A 
receptor, macrophages were pretreated with PTX, a nonse-
lective G protein-uncoupling agent, frequently used to exam-
ine the function of G protein-coupled receptors. As can be 
seen in Table 1, pretreatment with PTX blocked the Niacin-
mediated effect on pro-inflammatory cytokine production.  
 To induce the production of pro-inflammatory cytokines 
in vivo, mice were injected with 500 μg of LPS. As shown in 
Table 2, production of IL-1, TNF- and IL-6 for macro-
phages were significantly increased 12 h after LPS injection 
respect to PBS injected mice. Niacin treatment significantly 
reduced this elevated production of cytokines (Table 2).  
DISCUSSION 
 Novel therapeutic opportunities could emerge from the 
knowledge of the role of inflammation in atherosclerosis. In 
this context, we here demonstrate that Niacin acts directly 
upon macrophages to reduce the release of pro-inflammatory 
cytokines. These findings would point out its potential action 
in the prevention of atherosclerosis progression and in 
plaque stabilization. 
 Many studies have explored the relationship between 
dietary factors, changes in lipoprotein levels, and risk for 
atherosclerosis, particularly, the regulation of cholesterol and 
lipoprotein metabolism by the type and amount of dietary 
fat. Therefore we chose a diet with saturated fatty acids from 
animal origin (dairy butter) in order to induce an aortic le-
sion area in normal C57Bl/6J mice. This diet contains a 
higher percentage of fat, with no cholic acid or cholesterol 
addition, and it mimics human’s intake of fat. After six 
months, animals feed with this diet showed only a significant 
increase in plasma cholesterol levels without significant 
changes in the lipoprotein profile. However, the arteries wall 
sections of these animals showed significant alterations such 
as inner elastic layer disruption, disorganization of smooth 
muscle cells (SMC) from middle layer and vacuolization and 
ulterior migration of smooth muscle cells to the neointimal 
layer. Also, undifferentiated cells predominate in AGD arter-
 
Fig. (3). Niacin receptor characterization in macrophages. Panel 
A: Saturation Binding Assays: Increasing concentrations of [3H]-
Nicotinic acid were incubated with 6 x 106 macrophages during 3 h 
at 25ºC. Total (black) and non-specific (gray, in the presence of 0.1 
mM of Nicotinic acid) binding curves for [3H]-Nicotinic acid to 
isolated peritoneal macrophages from C57Bl/6J control mice were 
obtained. Panel B: Scatchard analysis of the results shown in panel 
A. The ratio of specific bound [3H]-Nicotinic acid to free (B/F) is 
plotted as a function of [3H]-Nicotinic acid bound (B). The inter-
cept with the abscissa is the number of binding sites (Bmax) and 
the negative reciprocal of the slope is the dissociation constant 
(Kd). A representative experiment from 5 independent assays per-
formed in duplicate is depicted in both panels. The Kd and Bmax 
values, mean ± S.E.M. from 5 experiments, for control and AGD 
mice macrophages are shown in the adjoined table. * p<0.05. 
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ies. In fact, these cells are responsive to factors that direct 
migration and proliferation to the tunica intima and then 
distort the normal intimal architecture leading to the obstruc-
tion of flow and restenosis [29]. Many studies tried to un-
ravel the role of SMC in atherosclerotic plaque formation. 
Initially the proliferation of these cells together with lipid 
infiltration of the intima was considered responsible for a 
slowly progressive process of plaque growth, eventually 
leading to lumen narrowing and ischemia [29]. By the other 
hand, SMC seem to protect the lesion against thrombosis, as 
they tend to encapsulate thrombogenic lipid together with 
macrophages and T-cells by means of forming a fibrous cap. 
Experimental models and analysis performed in human tis-
sues determined that the SMC is the main cellular compo-
nent in neointimal proliferation responsible for artery 
restenosis. Independently of the exact role that these SMC 
plays in arterial lesions, immunohistochemical findings ob-
served in AGD mice are indicative of the induction of 
atheroma formation. According to these results, Lukasova et 
al [30] have recently reported aortic atherosclerosis lesions 
in a mouse model of atherosclerosis in the absence of HDL 
increment. Moreover, they also showed that nicotinic acid 
inhibited disease progression under conditions that left total 
cholesterol levels and cholesterol distribution among VLDL, 
LDL and HDL fractions unaffected. This highlights the fact 
that that nicotinic acid can reduce the progression of athero-
sclerosis independently of its lipid-modifying effects. 
 Atherosclerosis could be considered as a systemic in-
flammatory disease. So, peritoneal macrophages, considered 
as systemic markers of inflammation, were used to study 
Niacin receptor expression and the effect of Niacin in the 
secretion of pro-inflammatory cytokines. Our results indicate 
that peritoneal macrophages from AGD mice showed a two 
fold increase in Niacin receptor number. The possibility 
arises that this increase could be due to IFN secreted by 
activated T cells, as was previously described [16]. In sup-
port to this, macrophages from LPS-injected mice displayed 
a two-fold increase in Niacin receptor number than control 
animals (data not shown), as was previously described for 
PUMA-G mRNA levels in macrophages from microbial 
septic mice (16). 
 As cytokine production in non-stimulated animals is very 
difficult to determine, for the analysis of Niacin action upon 
pro-inflammatory cytokines we used both in vitro and in vivo 
experimental approaches for this purpose. Results showed 
that macrophages from both control and AGD mice respond 
to a pro-inflammatory stimulus in vitro with increasing se-
cretion of TNF-, IL-1 and IL-6, but this increment was 
significantly higher in AGD than in control mice. Moreover, 
Niacin addition was able to decrease pro-inflammatory cyto-
kine secretion in both control and AGD mice, being the 
inhibitory effect more pronounced in AGD than in control 
animals (% inhibition for control and AGD mice, TNFα: 36 
vs 44%; IL-6: 31 vs 46%; IL-1: 19 vs 42 %). These results 
are in accordance with recently published findings [31] 
showing that Niacin is able to reduce secretion of stimulated 
pro-inflammatory mediators in a human acute monocytic 
leukemia cell line. On the other hand, Niacin in vivo treat-
ment was able to reduce pro-inflammatory cytokine produc-
tion in macrophages from mice injected with LPS. More-
over, it was described that Niacin significantly inhibited 
TNF-induced monocyte adhesion to cultured human aortic 
endothelial cells and activation of nuclear factor-kappa B 
(NF-κB) [19, 20].  
 
Fig. (4). Modulation of macrophage pro-inflammatory cytokine 
production by Niacin. Macrophages from control (white) or AGD 
(gray) mice were incubated in the presence or absence of increasing 
concentrations of Niacin (M) and stimulated with LPS (10 g/ml) 
+ IFN- (100 U/ml) for 24 h. Cytokine levels, namely IL-1 (Panel 
A), TNF- (Panel B) and IL-6 (Panel C) were measured in cell free 
supernatants, using commercial kits. Results shown are the mean ± 
SEM of 3 independent experiments performed in duplicate. + p< 
0.05 Basal (B) AGD vs Control mice; * p< 0.05, ** p<0.01 vs the 
corresponding B value.  
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CONCLUSIONS 
 These results suggest that Niacin, in addition to be a 
lipid-modifying drug, has a beneficial action by attenuating 
inflammatory mechanisms involved in atherosclerosis pa-
thology and plaque stabilization. Furthermore, the present 
results provide the basis for future studies on the potential 
contribution of Niacin to anti-inflammatory therapies. 
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Table 1. Effect of Pertussis Toxin (PTX) on Niacin (NA)-mediated Decrease of Stimulated Cytokine Secretion 











3194 ± 303   
2322 ± 267** 
2995 ± 298# 
 
3854 ± 321 
2256 ± 287** 


















3546 ± 294 
2123 ± 189** 
3721 ± 311# 
 
4247 ± 395 
2233 ± 227** 


















15442 ± 1670 
10456 ± 998** 
16028 ± 1687# 
 
21234 ± 1711 
10786 ± 1213** 
19999 ± 1532# 
Macrophages from control or AGD mice were pretreated with vehicle or PTX (50 ng/ml) for 18 h. After this time cells were incubated in the presence or 
absence of 1000 M of Niacin (NA) and stimulated with LPS (10g/mlIFN- (100 U/ml) for 24 h. Cytokine levels were determined as described in Fig (4). 
Data are mean ± S.E.M. of three experiments in each group. **p<0.01 vs the corresponding basal value, # p<0.05 respect NA value.  
Table 2. Niacin Action on Cytokine Production by Macrophages from Mice Injected with LPS 
Cytokines levels (pg/ml) 
Treatment 
IL-1ß TNF-α IL-6 
PBS Non detectable 23 ± 14 35± 18 
LPS 458 ± 57* 856 ± 101* 934 ± 123* 
PBS + Niacin Non detectable 19 ± 16 32 ± 25 
LPS + Niacin 209 ± 32* # 486 ± 52* # 492 ± 67* # 
Control mice were injected with PBS or LPS (20 mg/Kg) and were simultaneously orally treated with or without Niacin (250 mg/Kg). After 12 h, macro-
phages were collected and incubated for other 12 h in supplemented medium.  Cell free supernatants were obtained to determine cytokine levels as described 
in Fig. (4). Data are mean ± S.E.M. of three animals *p<0.05 respect the corresponding PBS injected mice, #p<0.05 respect the corresponding non Niacin 
treated mi 
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LIST OF ABBREVIATIONS 
AGD = atherogenic diet 
ELISA = enzyme-linked immunosorbent assays 
GPR109A = G-protein-coupled receptor that bind and 
be activated by Niacin 
HDL = High-density lipoprotein 
IFN- = interferon- 
IL-1 = Interleukin-1 
IL-6 = Interleukin-6 
LPS = lipopolysaccharide 
PTX = pertussis toxin 
PUMA-G = protein up-regulated by interferon-gamma 
Niacin receptor in mice macrophages 
SMC = smooth muscle cells 
TNF = Tumor Necrosis Factor-. 
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